Literature DB >> 17952107

Dosing in obesity: a simple solution to a big problem.

P Y Han1, S B Duffull, C M J Kirkpatrick, B Green.   

Abstract

The global epidemic of obesity has led to an increased prevalence of chronic diseases and need for pharmacological intervention. However, little is known about the influence of obesity on the drug exposure profile, resulting in few clear dosing guidelines for the obese. Here we present a semi-mechanistic model for lean body weight (LBW) that we believe is sufficiently robust to quantify the influence of body composition on drug clearance, and is therefore an ideal metric for adjusting chronic dosing in the obese.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952107     DOI: 10.1038/sj.clpt.6100381

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  65 in total

Review 1.  The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

Authors:  Sarah C McLeay; Glynn A Morrish; Carl M J Kirkpatrick; Bruce Green
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

2.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

3.  Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey.

Authors:  Michael A Barras; Carl M J Kirkpatrick; Bruce Green
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

4.  Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.

Authors:  Christophe Bardin; Estelle Nobecourt; Etienne Larger; François Chast; Jean-Marc Treluyer; Saik Urien
Journal:  Eur J Clin Pharmacol       Date:  2012-01-25       Impact factor: 2.953

Review 5.  Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.

Authors:  Neil S Horowitz; Alexi A Wright
Journal:  Gynecol Oncol       Date:  2015-04-12       Impact factor: 5.482

Review 6.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

7.  Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.

Authors:  Simone van Kralingen; Margot Taks; Jeroen Diepstraten; Ewoudt M van de Garde; Eric P van Dongen; Marinus J Wiezer; Bert van Ramshorst; Bart Vlaminckx; Vera H Deneer; Catherijne A Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2011-04-16       Impact factor: 2.953

8.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

9.  Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events.

Authors:  Michael A Barras; Stephen B Duffull; John J Atherton; Bruce Green
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

10.  A unified pharmacokinetic approach to individualized drug dosing.

Authors:  Evan J Begg; Paul K L Chin
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.